| Schedule of common stock outstanding |
The following table summarizes the common stock activity for the three and nine months ended September 30, 2021 and 2020:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
|
September 30, |
|
September 30, |
|
|
2021 |
|
|
|
2020 (1) |
|
|
|
2021 |
|
|
|
2020 (1) |
|
|
Common stock: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, beginning of period |
|
|
97,732,079 |
|
|
|
|
29,005,309 |
|
|
|
|
84,535,640 |
|
|
|
|
25,371,186 |
|
|
Issuance of common stock |
|
|
2,592,236 |
|
|
|
|
- |
|
|
|
|
15,788,675 |
|
|
|
|
3,634,123 |
|
|
Balance, end of period |
|
|
100,324,315 |
|
|
|
|
29,005,309 |
|
|
|
|
100,324,315 |
|
|
|
|
29,005,309 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Retroactively restated for Business Combination |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] |
The following instruments were excluded from the calculation of diluted shares outstanding because the effect of including them would have been anti-dilutive.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended September 30, |
|
|
For the Nine Months Ended September 30, |
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
Employee stock options |
|
5,518,473 |
|
|
|
7,072,426 |
|
|
|
10,642,260 |
|
|
|
7,072,426 |
|
Public Warrants |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Private Warrants |
|
- |
|
|
|
- |
|
|
|
3,914,525 |
|
|
|
- |
|
Restricted shares |
|
3,035,676 |
|
|
|
- |
|
|
|
3,035,676 |
|
|
|
- |
|
Legacy Danimer options |
|
- |
|
|
|
1,805,555 |
|
|
|
125,490 |
|
|
|
1,805,555 |
|
Legacy Danimer warrants |
|
- |
|
|
|
506,611 |
|
|
|
- |
|
|
|
506,611 |
|
Total excluded instruments |
|
8,554,149 |
|
|
|
9,384,592 |
|
|
|
17,717,951 |
|
|
|
9,384,592 |
|
|